Figure 2From: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trialsCombined Results - Efficacy Outcomes (PFS, OS). CI: confidence intervals; A: anthracyclines; T: taxanes; Cap: capecitabine; Beva: bevacizumab; PFS: progression free survival; OS: overall survival.Back to article page